Quantcast
Environmental News for a Healthier Planet and Life

Coronavirus: The Tide Is Coming for Medicinal Cannabis

Health + Wellness
Coronavirus: The Tide Is Coming for Medicinal Cannabis

Bloomberg Creative / Bloomberg Creative Photos / Getty Images

By Zulfikar Abbany

The search for a vaccine for the new coronavirus, SARS-CoV-2, or indeed a medicinal drug to cure it, has taken researchers down both traditional and less traditional avenues.


They have looked at existing drug candidates, such as remdesivir, which was original developed to treat Ebola. In Germany, the first clinical trials for a coronavirus vaccine are based on a candidate developed for cancer immunology.

There's a study out of France that suggests nicotine — typically ingested via the often-lethal pastime of smoking — may protect people against the novel coronavirus, itself a potentially fatal lung infection.

And, now, preliminary research is emerging out of Canada that certain strains of the psychoactive drug cannabis may also increase resistance to the coronavirus. If the study, which is not yet peer reviewed, can be verified, it would appear that cannabis works in a similar way to nicotine.

"The results on COVID-19 came from our studies on arthritis, Crohn's disease, cancer and others," said Dr. Igor Kovalchuck, a professor of Biological Sciences at the University of Lethbridge, in an email to DW.

Blocking Gateways 

As with the research into nicotine's effect on the coronavirus, it is thought that some strains of cannabis reduce the virus' ability to enter the lungs, where it takes hold, reproduces and spreads.

In a paper on preprints.org, where scientists can publish non-peer-reviewed results, Kovalchuck and colleagues write that their specially developed strains of cannabis effectively stop the virus from entering the human body.

The study is one of many papers globally that have been shared on preprint websites, including preprints.org, in a bid to disseminate preliminary findings into potential COVID-19 treatments that have yet to undergo rigorous peer review.

The coronavirus needs a "receptor" to enter a human host. That receptor is known as an "angiotensin-converting enzyme II," or ACE2.

ACE2 is found in lung tissue, in oral and nasal mucus, in the kidneys, testes, and gastrointestinal tracts, they write.

And the theory is that by modulating ACE2 levels in those "gateways" to the human host, it may be possible to lower our susceptibility, or vulnerability, to the virus. It could basically reduce our risk of infection.

"If there's no ACE2 on tissues, the virus will not enter," said Kovalchuck.

No Common or Garden Cannabis

Some in the science community say medicinal cannabis may help to treat a range of conditions from nausea to dementia. But medicinal cannabis is not the same as what you might call recreational cannabis.

Those more "common or garden varieties" of cannabis — or street cannabis — are known for their Tetrahydrocannabinol (THC) content. That's the main psychoactive agent in the drug.

The Alberta-based researchers, meanwhile, have focused on strains of the plant, Cannabis sativa, that are high in an anti-inflammatory cannabinoid, cannabidiol (CBD) — one of the other main chemicals in cannabis, aside from THC.

They have developed more than 800 new Cannabis sativa variants, with high levels of CBD, and identified 13 extracts which they say modulate ACE2 levels in those humans gateways.

"Our varieties are high in CBD, or balanced CBD/THC, because you can give a higher dose and people will not be impaired due to the psychoactive properties of THC," said Kovalchuck.

Low Funding, Low Knowledge

Kovalchuck also heads a company called Inplanta BioTechnology, with Dr. Darryl Hudson, who has a PHD from the University of Guelph — another Canadian institute where research is ongoing into the use of cannabinoids in medicine.

But funding for cannabinoid research is "still hard," he said. And that's the case in other countries, too.

Some researchers in the UK say that may be because there are misconceptions among the general public and politicians about medicinal cannabis, perhaps even a fear that people will become addicted or try to self-medicate, using just any old form of cannabis they can find.

Those researchers say themselves that it is vital to be clear about the information and to avoid sensationalism.

"Researchers have to be particularly careful when disseminating their results given the socio-political volatility of medicinal cannabis use," said Chris Albertyn, a Research Portfolio Lead at King's College London, and an expert on cannabinoids and dementia.

The best way to get through that, says Albertyn, is to implement open, transparent research methods.

"In this instance, the current research from Canada has just unveiled a potential therapeutic 'mechanism of action' but that would need to be validated and tested in well-designed, robust clinical trials before any meaningful clinical conclusions can be drawn," he said.

That would include pre-registering clinical protocols and analysis methods, publishing in open access journals, double-blind placebo controlled trials, and strict, independent peer review by the clinical academic community, said Albertyn.

A turning tide

The problem is that without sufficient funding and further research, there is too little knowledge about cannabinoids — whether it's positive or negative research results — some say we just won't know until we do the research.

"But there is ENORMOUS interest now," said Kovalchuk in his email. And that's his emphasis. "The tide is coming."

While he and his co-authors say even their most effective extracts require large-scale validation, they say they may be a "safe addition" to the treatment of COVID-19. An addition, mind, alongside other treatments.

So, large-scale verification pending, medicinal cannabis could be developed into "easy-to-use preventative treatments," such as a mouthwash or a throat gargle in both clinical and home use.

Reposted with permission from Deutsche Welle.

Yves Adams / Instagram

A rare yellow penguin has been photographed for what is believed to be the first time.

Read More Show Less

EcoWatch Daily Newsletter

The Crystal building in London, England is the first building in the world to be awarded an outstanding BREEAM (BRE Environmental Assessment Method) rating and a LEED (Leadership in Energy and Environmental Design) platinum rating. Alphotographic / Getty Images

By Stuart Braun

We spend 90% of our time in the buildings where we live and work, shop and conduct business, in the structures that keep us warm in winter and cool in summer.

But immense energy is required to source and manufacture building materials, to power construction sites, to maintain and renew the built environment. In 2019, building operations and construction activities together accounted for 38% of global energy-related CO2 emissions, the highest level ever recorded.

Read More Show Less

Trending

Houses and wooden debris are shown in flood waters from Hurricane Katrina Sept. 11, 2005 in New Orleans, Louisiana. Jerry Grayson / Helifilms Australia PTY Ltd / Getty Images

By Eric Tate and Christopher Emrich

Disasters stemming from hazards like floods, wildfires, and disease often garner attention because of their extreme conditions and heavy societal impacts. Although the nature of the damage may vary, major disasters are alike in that socially vulnerable populations often experience the worst repercussions. For example, we saw this following Hurricanes Katrina and Harvey, each of which generated widespread physical damage and outsized impacts to low-income and minority survivors.

Read More Show Less
A gray wolf is seen howling outside in winter. Wolfgang Kaehler / Contributor / Getty Images

Wisconsin will end its controversial wolf hunt early after hunters and trappers killed almost 70 percent of the state's quota in the hunt's first 48 hours.

Read More Show Less
Tom Vilsack speaks on December 11, 2020 in Wilmington, Delaware after being nominated to be Agriculture Secretary by U.S. President Joe Biden. Jim Watson / AFP / Getty Images

By Jessica Corbett

Sen. Bernie Sanders on Tuesday was the lone progressive to vote against Tom Vilsack reprising his role as secretary of agriculture, citing concerns that progressive advocacy groups have been raising since even before President Joe Biden officially nominated the former Obama administration appointee.

Read More Show Less